Amgen reported 20% weight loss in its MariTide Phase II study results, but a 10% drop in share price suggests investors had ...
The Phase III trial of AXS-12 showed results over placebo as the company looks towards a new drug application for its ...
The company’s oral, microbiome-changing therapy was well tolerated in patients with amyotrophic lateral sclerosis.
AstraZeneca has reported positive results from a Phase III trial that evaluated Truqap combined with abiraterone and ADT for ...
MSD has reported that the Phase III ZENITH trial of WINREVAIR for pulmonary arterial hypertension met its primary endpoint.